OraSure Technologies Toekomstige groei

Future criteriumcontroles 0/6

De omzet en winst van OraSure Technologies zullen naar verwachting dalen met respectievelijk 15.8% en 47.7% per jaar. De winst per aandeel zal naar verwachting afnemen met 47.1% per jaar. Het rendement op het eigen vermogen zal naar verwachting 2.2% in 3 jaar.

Belangrijke informatie

-47.7%

Groei van de winst

-47.1%

Groei van de winst per aandeel

Medical Equipment winstgroei	17.1%
Inkomstengroei	-15.8%
Toekomstig rendement op eigen vermogen	2.2%
Dekking van analisten	Low
Laatst bijgewerkt	11 Nov 2024

Recente toekomstige groei-updates

Here's What Analysts Are Forecasting For OraSure Technologies, Inc. (NASDAQ:OSUR) After Its Third-Quarter Results

Nov 08

Recent updates

Some May Be Optimistic About OraSure Technologies' (NASDAQ:OSUR) Earnings

Nov 14

Here's What Analysts Are Forecasting For OraSure Technologies, Inc. (NASDAQ:OSUR) After Its Third-Quarter Results

Nov 08

OraSure: An NCAV Diamond In The COVID Rough

Nov 04

OraSure Technologies: Nursing A COVID-19 Hangover

Sep 10

OraSure Technologies, Inc. (NASDAQ:OSUR) Just Reported Earnings, And Analysts Cut Their Target Price

May 11

Lacklustre Performance Is Driving OraSure Technologies, Inc.'s (NASDAQ:OSUR) Low P/S

Apr 17

Earnings Beat: OraSure Technologies, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Mar 01

Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing

Feb 29

OraSure Technologies, Inc.'s (NASDAQ:OSUR) Business And Shares Still Trailing The Industry

Dec 20

Returns On Capital At OraSure Technologies (NASDAQ:OSUR) Have Stalled

Nov 08

Industry Analysts Just Upgraded Their OraSure Technologies, Inc. (NASDAQ:OSUR) Revenue Forecasts By 14%

Aug 09

Analysts Have Just Cut Their OraSure Technologies, Inc. (NASDAQ:OSUR) Revenue Estimates By 12%

May 16

Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing

May 13

Party Time: Brokers Just Made Major Increases To Their OraSure Technologies, Inc. (NASDAQ:OSUR) Earnings Forecasts

Feb 17

Are OraSure Technologies, Inc. (NASDAQ:OSUR) Investors Paying Above The Intrinsic Value?

Jun 14

OraSure: Not So Sure With Softening Fundamentals, Fairly Priced At $2.54

Jun 10

Winst- en omzetgroeiprognoses

NasdaqGS:OSUR - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	155	-9	-1	4	5
12/31/2025	147	-17	N/A	5	5
12/31/2024	186	-13	24	30	5
9/30/2024	224	11	64	69	N/A
6/30/2024	274	27	86	93	N/A
3/31/2024	305	23	134	142	N/A
12/31/2023	405	54	131	142	N/A
9/30/2023	453	49	76	82	N/A
6/30/2023	480	44	50	62	N/A
3/31/2023	475	30	-25	-5	N/A
12/31/2022	387	-17	-111	-47	N/A
9/30/2022	328	-43	-129	-42	N/A
6/30/2022	265	-64	-162	-77	N/A
3/31/2022	243	-47	-152	-67	N/A
12/31/2021	234	-23	-83	-35	N/A
9/30/2021	233	-11	-62	-19	N/A
6/30/2021	227	5	-39	5	N/A
3/31/2021	199	-4	-36	-1	N/A
12/31/2020	172	-15	-23	6	N/A
9/30/2020	158	-14	-14	1	N/A
6/30/2020	146	-2	-9	3	N/A
3/31/2020	156	13	0	12	N/A
12/31/2019	155	17	0	10	N/A
9/30/2019	150	25	17	25	N/A
6/30/2019	159	20	22	30	N/A
3/31/2019	161	19	25	32	N/A
12/31/2018	182	20	33	39	N/A
9/30/2018	177	17	16	23	N/A
6/30/2018	174	15	N/A	20	N/A
3/31/2018	174	16	N/A	23	N/A
12/31/2017	166	31	N/A	28	N/A
9/30/2017	145	31	N/A	30	N/A
6/30/2017	135	31	N/A	30	N/A
3/31/2017	126	30	N/A	32	N/A
12/31/2016	123	20	N/A	25	N/A
9/30/2016	125	17	N/A	26	N/A
6/30/2016	123	12	N/A	36	N/A
3/31/2016	122	11	N/A	27	N/A
12/31/2015	120	8	N/A	16	N/A
9/30/2015	116	1	N/A	14	N/A
6/30/2015	114	1	N/A	15	N/A
3/31/2015	110	1	N/A	9	N/A
12/31/2014	106	-5	N/A	8	N/A
9/30/2014	107	4	N/A	20	N/A
6/30/2014	103	1	N/A	7	N/A
3/31/2014	101	-7	N/A	8	N/A
12/31/2013	99	-11	N/A	8	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De winst van OSUR zal naar verwachting de komende 3 jaar dalen ( -47.7% per jaar).

Winst versus markt: De winst van OSUR zal naar verwachting de komende 3 jaar dalen ( -47.7% per jaar).

Hoge groeiwinsten: De winst van OSUR zal naar verwachting de komende 3 jaar dalen.

Omzet versus markt: De omzet van OSUR zal naar verwachting de komende 3 jaar dalen ( -15.8% per jaar).

Hoge groei-inkomsten: De omzet van OSUR zal naar verwachting de komende 3 jaar dalen ( -15.8% per jaar).

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen OSUR zal naar verwachting over 3 jaar laag zijn ( 2.2 %).

OraSure Technologies Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Here's What Analysts Are Forecasting For OraSure Technologies, Inc. (NASDAQ:OSUR) After Its Third-Quarter Results

OraSure Technologies, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024

Consensus EPS estimates upgraded to US$0.098 loss

OraSure Technologies, Inc. Provides Revenue Guidance for the Third Quarter of 2024

Price target decreased by 7.5% to US$6.13

Consensus EPS estimates fall by 54%

Recent updates

Some May Be Optimistic About OraSure Technologies' (NASDAQ:OSUR) Earnings

Here's What Analysts Are Forecasting For OraSure Technologies, Inc. (NASDAQ:OSUR) After Its Third-Quarter Results

OraSure Technologies, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024

New minor risk - Profit margin trend

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

OraSure: An NCAV Diamond In The COVID Rough

OraSure Technologies, Inc. to Report Q3, 2024 Results on Nov 06, 2024

OraSure Technologies, Inc. Appoints John P. Kenny as New Member of the Board, Member of the Nominating and Corporate Governance Committee

OraSure Technologies: Nursing A COVID-19 Hangover

Consensus EPS estimates upgraded to US$0.098 loss

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. Provides Revenue Guidance for the Third Quarter of 2024

OraSure Technologies, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Price target decreased by 7.5% to US$6.13

Consensus EPS estimates fall by 54%

Price target decreased by 7.9% to US$6.95

OraSure Technologies, Inc. (NASDAQ:OSUR) Just Reported Earnings, And Analysts Cut Their Target Price

New minor risk - Shareholder dilution

OraSure Technologies, Inc. Provides Revenue Guidance for the Second Quarter of 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lacklustre Performance Is Driving OraSure Technologies, Inc.'s (NASDAQ:OSUR) Low P/S

New minor risk - Shareholder dilution

OraSure Technologies, Inc., Annual General Meeting, May 14, 2024

Earnings Beat: OraSure Technologies, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

New minor risk - Earnings quality

OraSure Technologies, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing

Full year 2023 earnings: EPS exceeds analyst expectations

OraSure Technologies, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Chief Product Officer notifies of intention to sell stock

OraSure Technologies, Inc.'s (NASDAQ:OSUR) Business And Shares Still Trailing The Industry

Investor sentiment improves as stock rises 18%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. Provides Financial Guidance for the Fourth Quarter 2023

Returns On Capital At OraSure Technologies (NASDAQ:OSUR) Have Stalled

OraSure Technologies, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Investor sentiment improves as stock rises 41%

Industry Analysts Just Upgraded Their OraSure Technologies, Inc. (NASDAQ:OSUR) Revenue Forecasts By 14%

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. Provides Revenue Guidance for the Third Quarter of 2023

OraSure Technologies, Inc. to Report Q2, 2023 Results on Aug 03, 2023

OraSure Technologies, Inc. Announces Election of Robert W. McMahon to its Board of Directors, Effective July 31, 2023

Price target decreased by 7.2% to US$6.45

OraSure Technologies, Inc. Announces Study Concludes Self-Sampling Using Colli-Pee® Device for HPV Screening Is Both Cost Effective and Could Improve Patient Access

Investor sentiment improves as stock rises 17%

Chief Financial Officer recently bought US$493k worth of stock

Investor sentiment deteriorates as stock falls 22%

Analysts Have Just Cut Their OraSure Technologies, Inc. (NASDAQ:OSUR) Revenue Estimates By 12%

Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing

Price target increased by 13% to US$6.95

Orasure Technologies, Inc. Provides Earnings Guidance for the Second Quarter 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. to Report Q1, 2023 Results on May 10, 2023

Party Time: Brokers Just Made Major Increases To Their OraSure Technologies, Inc. (NASDAQ:OSUR) Earnings Forecasts

Price target increased by 8.0% to US$5.88

Full year 2022 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. Provides Revenue Guidance for the First Quarter of 2023

OraSure Technologies, Inc. to Report Q4, 2022 Results on Feb 14, 2023

We're Not Very Worried About OraSure Technologies' (NASDAQ:OSUR) Cash Burn Rate

Consensus estimates of losses per share improve by 69%

High number of new directors

OraSure Technologies, Inc. Announces Executive Changes

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

OraSure Technologies, Inc. Reports Goodwill and Long-Lived Assets Impairment Charges for the Third Quarter Ended September 30, 2022

Orasure Technologies Receives General Clearance for Its ORAcollect--Dx Device for over the Counter Use from the U.S. Food and Drug Administration

OraSure Technologies, Inc. Announces InteliSwab Covid-19 Rapid Test Now Available in Amazon’s Online Store

OraSure Technologies, Inc. to Report Q3, 2022 Results on Nov 08, 2022

OraSure wins $8.6M government contract for next-gen Ebola test